The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, commonly known as statins, are the drugs of choice for the pharmacotherapy of hyperlipidemia as well as for reducing atherosclerotic cardiovascular risk. Mechanisms behind the neuroprotective potential of rosuvastatin can be attributed to its pleiotropic effects, independent of its ability to inhibit HMG-CoA reductase.
| INTRODUC TI ON
The 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors, commonly known as statins, are the drugs of choice for the pharmacotherapy of hyperlipidemia as well as for reducing atherosclerotic cardiovascular risk. 1 Statins inhibit the HMGCoA reductase enzyme and therefore suppress the conversion of HMG-CoA into mevalonate-the first step in cholesterol biosynthesis. Following this step, low-density lipoprotein-cholesterol synthesis is lowered in hepatocytes, which consequently leads to a reduced blood cholesterol level. Despite this long known potent lipid-lowering effect, statins also possess lipid-independent pharmacological effects or pleiotropic effects. 2 Recently, there has been an increased interest in evaluating the potential use of statins for treating numerous neurological disorders. 3, 4 Several pre-clinical and clinical trials substantiate the neuroprotective effect of statins in a plethora of neurological disorders such as Alzheimer's disease, Parkinson's, multiple sclerosis, epilepsy, spinal cord injury, depression, cognitive dysfunction, and stroke. [3] [4] [5] [6] Possible reasons behind the neuroprotective effect of statins may be attributed to their anti-inflammatory, antioxidant, anti-apoptotic, and anti-excitotoxicity activities. 7 Interestingly, of all the statins, rosuvastatin is comparatively the most potent. It exhibits greater affinity for the active site of HMG-CoA reductase as evident in STELLAR, DISCOVERY and the Discovery Belux studies. 8 Although statins contain both hydrophilic and lipophilic moieties, the hydrophilic nature of rosuvastatin is more prominent. 9 Rosuvastatin possesses an atypical N-methyl N-linked sulphonamide moiety along with a wholly substituted pyrimidine nucleus. Further, X-ray crystallography studies have revealed that rosuvastatin had the most number of protein-ligand interactions when compared to any other member of this family ( Figure 1 ). 10 It is metabolized slowly by hepatic enzymes, particularly CYP2C19 and CYP2C9 and its duration of action and plasma half-life are higher than any other statin. 11 Escalating evidence suggests that rosuvastatin, apart from its hypolipidaemic effects, exerts multiple beneficial pleiotropic immunomodulatory, anti-inflammatory, anti-apoptotic and anti-excitotoxic actions. 12 These pleiotropic, cholesterol-independent effects include increase in endothelial NO synthase (NOS) and tissue-type plasminogen Mechanisms behind the neuroprotective potential of rosuvastatin can be attributed to its pleiotropic effects, independent of its ability to inhibit HMG-CoA reductase. Rosuvastatin has also been shown to inhibit the upregulation of gp91phox and p22phox, which along with the aforementioned pharmacodynamic actions have suggested that pretreatment with rosuvastatin may be a promising therapeutic strategy for cerebral ischaemia/reperfusion injury, through attenuation of oxidative stress and inflammation. 19 Another study demonstrated that heme oxygenase-1 (HO-1) is a target site and antioxidant mediator of rosuvastatin in endothelial cells. 20 In recent years, HO-1 has emerged as an important mediator of antioxidants and has been found to exhibit a central role in cellular antioxidant defense in various tissues including heart, kidney, and neuronal cells. 21 Further, a study revealed that rosuvastatin elicited dose-dependent delayed protection against excitotoxic stress. The mechanism involved was reduced Ca 2+ influx and subsequent decreased superoxide anion production allowing neuronal survival. 22 By mitigating the formation of hyperphosphorylated tau protein, rosuvastatin might delay the progression of Alzheimer's disease.
Data collected from molecular docking studies in our laboratory has confirmed that rosuvastatin has good binding with targets such as NF-ĸB, acetylcholinesterase (AChE) and amyloid beta (Aβ), which corroborates the role of rosuvastatin in amelioration of cognitive impairment. [23] [24] [25] [26] In light of such intriguing research findings, the present review elaborates upon the neuroprotective effects of rosuvastatin in different neurological disorders as well as talks about the various possible pharmacodynamic mechanisms that might be behind these pleiotropic effects (Figure 2 ). The upcoming sections will explicitly discuss the therapeutic prospect of rosuvastatin in neuroinflammation, Alzheimer's, Parkinson's, cerebral ischaemia, spinal cord injury, and epilepsy along with the mechanistic pathways involved (as given in Table 1 ).
| ME THODOLOGY
The publications on Google Scholar, PubMed, and Science Direct were searched with the search strings "Rosuvastatin," "Neuro,"
"Brain" in combination with each other with no particular time restriction in order to get a holistic and comprehensive view of the research done on this topic so far.
| Rosuvastatin in neuroinflammation
Neuroinflammation constitutes a common aetiological pathway in neurological disorders. 27 The NF-κB and ROS are actively involved in the neuroinflammatory cascade, and it has been found that rosuvastatin administration significantly reduces the expression of NF-κB. 28 In another study in which the cognitive dysfunction was induced in albino rats by high salt and high cholesterol diet, there was significant involvement of proinflammatory markers such as TNF-alpha and IL-10. 29 Rosuvastatin administration attenuated the expression of proinflammatory markers and exerted a significant neuroprotective effect. Similarly, in an in vitro study using pure microglial culture driven from forebrain of 18-day-old rat embryo, rosuvastatin effectively inhibited cell adhesion and astrocytes. 30 In addition, rosuvastatin blocked the expression of proinflammatory markers (IL-1 beta, TNF-alpha) and anti-inflammatory marker (IL-10). 29 In another study of early brain injury (EBI) by subarachnoid haemorrhage (SAH) using endovascular perforation SAH model, neuroprotective role of rosuvastatin was evaluated by Uekawa et al. In this study, male Sprague
Dawley rats were pretreated with rosuvastatin at the dose of 10 mg/ kg, po, once daily from 7 days before to 1 day after the SAH operation for 7 days and after 22 hours of SAH induction. The protective Of all 36 patients, 19 received rosuvastatin and 17 were given a placebo. The best-fit mixed model showed a significant effect of rosuvastatin on the reduction of tumour necrosis factor-α levels (P = 0.004), whereas rosuvastatin treatment did not affect the levels of IL-1β, IL-6, and IL-10. 33 Thus, the authors suggested that statins may induce an anti-inflammatory effect and may promote recovery after TBI. The above findings suggest that rosuvastatin can serve as a promising future medication in the management of inflammationrelated neurological conditions.
| Rosuvastatin and Alzheimer's disease
Alzheimer's disease (AD) is a chronic condition characterized by the deposition of amyloid beta peptide and senile plaque that further leads to the formation of hyperphosphorylated tau protein. 34 Reportedly, amyloid beta also induces the formation of ROS and RNS. 35 It has also been reported to aggravate calcium-mediated excitotoxicity and alteration of synaptic function which halts learning and memory. 36 Recent evidence has shown an association between cholesterol and AD. Population-based studies further strengthen this relation since hypercholesterolaemia is related to increased F I G U R E 2 Illustration depicting potential mechanism underlying rosuvastatin-mediated attenuation of neurodegeneration via blocking isoprenylation in mevalonate pathway. The inhibition of isoprenylation further inhibits the synthesis of isoprenoid intermediates, ie, GTPases, including Rho, Rac and Rock, which are primarily responsible for major pleiotropic effects of rosuvastatin. A, Rosuvastatin may prevent neuroinflammation by inhibiting synthesis of DNA in neuronal cell which could further inhibit gene transcription of nuclear factor kappa beta (NF-κβ), a key inflammatory mediator. B, Rosuvastatin may impact neuronal cell apoptosis by preventing non-specific phagocytosis mediated by the Rho Rac system. C, Rosuvastatin-mediated polymerization of endothelial actin microfilaments decreases the stability of eNOS (endothelial nitric oxide synthase) mRNA and alternatively increases the production of iNOS (inducible nitric oxide synthase) resulting in enhancing nitric oxide (NO) bioavailability leading to improved cerebral blood flow and protection from ischaemic stroke. D, Rosuvastatin inhibits NADPH oxidase activation that further reduces formation of reactive oxygen species thereby preventing oxidative stress. E, Rosuvastatin may prevent dementia by promoting axonal regeneration Further, amyloid beta peptide with mitochondrial stress contributes to the oxidative stress. 38 Amyloid beta production and induced oxidative stress are well mitigated by statins as evident in many animal models. Statins are also reported to correct cognitive dysfunction induced by amyloid beta protein. 39 Increase in cerebral blood flow and attenuation of oxidative stress, inflammation and reduction in the level of amyloid beta proteins are the apparent reported effects of statins. 40 In accordance with recent epidemiological studies, patients taking rosuvastatin for hyperlipidaemia were found to be on significantly lower risk of developing AD. 41 Interestingly, rosuvastatin has been reported to exert an anti-apoptotic effect in human neuroblastoma cells when exposed to Aβ . In the same study, reduction in caspase-3 activity and increase in alpha-secretase levels was also observed making it a first of its kind study that demonstrated the efficacy of hydrophilic statin (rosuvastatin) against Aβ 1-42 -induced AD. 42 High cholesterol diet triggers the microglial load and induces neuroinflammation, which contributes to the progression of AD.
Rosuvastatin treatment lowers the microglial burden and mitigates the inflammatory cascade. 23 In another study, AD was induced by the administration of scopolamine in a mouse model at the dose of 1 mg/kg per day for 2 weeks and rosuvastatin was administered at a dose of 20 mg/kg per day for 2 weeks. 43 Amelioration of memory dysfunction induced by scopolamine was observed in the study, but it was statistically insignificant. Molecular docking of rosuvastatin with Aβ 1-42 and AChE and result showed that the rosuvastatin had good binding with Aβ and AChE. In line with this study, it has also been found that rosuvastatin effectively counterbalances the inflammation induced by high salt and cholesterol diet. Rosuvastatin reduces the production of nitric oxide, tumour necrosis factor, NF-κB and interleukin 10 in the CA1 region of the hippocampus. 28 Taking together the results of all these studies, it can be concluded that rosuvastatin can be effectively used in the symptomatic management of AD and related cognitive dysfunction, although additional clinical studies are required to bring rosuvastatin from bench to bedside.
| Rosuvastatin and Parkinson's disease
Parkinson's disease (PD) is the second most common neurodegenerative disease and is characterized by marked depletion of dopaminergic neurons in the substantia nigra pars compacta of the basal ganglia and a subsequent malfunction of the nigrostriatal circuitry. 44 The cause of PD includes possible mechanisms involving oxidative stress, immunoinflammatory responses, mitochondrial dysfunction, and proteasome dysfunction. 45 The observed link between lower PD risk and statin use is consistent with the results of animal and in vitro experimental studies in PD models. A study demonstrated that simvastatin effectively blocked the activation of astrocytes, reduced TNF-α expression, thus protecting the dopaminergic neurons in the substantia nigra and striatum in a rat model of PD. 46 Recent research findings demonstrated that statins might exert neuroprotective effects by lowering alpha-synuclein aggregation and regulating NMDA receptors. 47 Moreover, in vitro studies have elucidated that simvastatin provides neuroprotection against dopaminergic neurodegeneration, not only via anti-inflammatory mechanisms, the PI3K/Akt/caspase 3 pathway, but also by inhibiting reactive oxygen species production. 48 Furthermore, a study investigating the effects of statin on autophagy markers and evaluating the neuroprotective effect of rosuvastatin against rotenone-induced neurotoxicity 
AChE, acetylcholinesterase; AD, Alzheimer disease; AMPK, 5′ adenosine monophosphate-activated protein kinase; APP, amyloid precursor protein; Aβ, amyloid beta; BAX, Bcl-2 associated X protein; Ccl24, eotaxin-2; CCR, C-C chemokine receptor type; CI, cerebral injury; COX, cyclo-oxygenase; Cxcl1, chemokine (C-X-C motif) ligand 1; CXCR2, C-X-C chemokine receptor type; eNOS, endothelial nitric oxide synthase; EP, epilepsy; ERK1/2, extracellular signal-regulated kinases; Hspb1, heat shock protein beta- 
| Rosuvastatin and cerebral ischaemia
At present, the possible cerebroprotective potential of rosuvastatin in brain ischaemia-reperfusion injury via interfering with inflammatory, oxidative, and apoptotic pathways was thoroughly investigated by researchers worldwide. Interestingly, these study findings clearly demonstrated that cerebral ischaemia-reperfusion injury could be effectively ameliorated by rosuvastatin via its anti-inflammatory, anti-apoptotic and antioxidant effects. 50 Brain trauma is more often associated with ischaemia, which accounts for a large number of deaths worldwide. 51 The proposed mechanism involving trauma/stroke/ischaemia includes either the reduced production of biochemical responsible for vasodilation or overproduction of vasoconstricting biochemicals. Platelet aggregation, neuroinflammation, oxidative stress further aggravates the symptoms of brain trauma. 52 Strokes comprise two types-ischaemic refers to lack of blood, whereas haemorrhagic refers to excessive bleeding. 53 Ideally, there is no standard therapy for stroke and anticoagulants, and sometimes aspirin is used. Clopidogrel and ticlopidine are sometimes prescribed, as adjuvant therapy in conjunction with aspirin. Thus, there is an urgent need of therapeutics which can act with an umbrella mode of action. 45 Statins are emerging as a potent class of drugs that have been reported to possess beneficial effects in post recovery, as well as pretreatment, preventing the onset and reducing the severity of stroke in in vivo studies of transit middle cerebral artery occlusion. 54 Recently, a study was conducted to evaluate whether rosuvastatin therapy can reduce stroke rates in patients with low cholesterol, but elevated C-reactive protein.
Rosuvastatin was administered at a dose of 20 mg/kg and follow-up was done for 1.9-5 years. The outcome of this study showed reduction of more than half of ischaemic stroke among volunteers. 49 Post-stroke improvement has always been a challenging task for clinicians. Thus, in a pre-clinical study in 129/SV wild-type mice evaluating rosuvastatin at doses of 0.2 and 20 mg/kg, it was found that intravenous administration of rosuvastatin given after 4 hours of MCAO reduced lesion size, whereas ip administration imparted protection only at the dose of 20 mg/kg. Also, intravenous administration of rosuvastatin exerted post-stroke recovery property by increasing the level of phosphorylated Akt and eNOS synthase activity in vasculature. 57 Rosuvastatin treatment seems to be potentially promising in ischaemic stroke treatment as it has reportedly been found to increase grip strength and motor coordination, reduce anxiety, increase neuronal survival and lead to overall neurological recovery. 58 In another clinical study, 476 acute ischaemic stroke patients were treated with tissue plasminogen activator (tPA) to investigate the relationship between prior statin use and functional outcome at 3 months, the occurrence of symptomatic intracerebral haemorrhage and early in-hospital mortality. The study findings were indicative of better functional outcome in patients prior to statin therapy and treated with tPA for acute ischaemic stroke than statin-naive patients. 59 Recently a single-centric, prospective, ran- 
| Rosuvastatin and spinal cord injury
Spinal cord injury is a disorder for which lifelong pharmacotherapy is required. The basic mechanism involved in spinal cord injury includes the compression of neural elements by damaged bone, axonal disruption and ligament damage peripherally as well as in the central nervous system followed by swelling in the spinal cord, which further leads to ischaemia. 61 There is always a possibility of systemic hypotension, which again exacerbates ischaemia. Moreover, release of toxic material from damaged neuronal membrane causes secondary injury. 62 The basic pharmacological treatment includes the use of methylprednisolone. Positive results are achieved with this drug in terms of reducing swelling, inflammation, reduction in free radical activity and diminished glutamate release are observed if given within 8 hours of injury.
However, high dose of methylprednisolone leads to wound infection and gastric bleeding. 63 Other treatment approaches include the use of monosialoganglioside, naloxone, tirilazad, and AMPA receptor antagonists, but the primary endpoint is not achieved with any of the drugs. 64 Thus, there is an unmet need for therapy, which can cover all aspects of traumatic as well as non-traumatic brain injury.
Nowadays, statins are emerging as a potent choice of drug in spinal cord injury. In a pre-clinical study, spinal cord injury was induced in rats by ischaemia/reperfusion. 
| Rosuvastatin and epilepsy
Since decades, epilepsy has been considered as a neuronal disorder, and very little importance has been given to the non-neuronal aspect of epilepsy. 68 Growing evidence suggests the involvement of inflammation, blood-derived leukocytes, oxidative stress, and damage of blood-brain barrier in the aetiology and progression of epilepsy. 69 
| CON CLUS ION
The effectiveness of rosuvastatin in numerous neurological disorders such as epilepsy, Alzheimer's disease, Parkinson's disease, spinal cord injury, and cerebral ischaemia is becoming more apparent, as evident in recent research studies. The possible reason for the neuroprotective effect of rosuvastatin could be broadly attributed to its anti-inflammatory, antioxidant, and anti-apoptotic activity. In conclusion, the broad therapeutic activity of rosuvastatin in neurological disorders potentially through its multifactorial modes of action emphasizes the need of further pre-clinical and clinical studies to elucidate its pharmacodynamics and translate rosuvastatin into a drug of choice for the numerous neurological disorders it has been found exceedingly effective for. 
ACK N OWLED G EM ENT

CO N FLI C T O F I NTE R E S T
There are no conflicts of interest to declare.
O RCI D
Tushar Madaan http://orcid.org/0000-0003-0944-1091
Abul K. Najmi http://orcid.org/0000-0002-6500-2686
